News

vTv Therapeutics is recruiting patients for a large Phase 3 study, known as STEADFAST, assessing the drug azeliragon as a potential treatment for mild Alzheimer’s disease (AD). Study participants will be randomly assigned to take either a 5 mg pill containing azeliragon once a day, or a placebo (sugar pill), for 18 months, with…

Unbalanced, unhealthy zinc levels show in many diseases including Alzheimer’s disease, Parkinson’s disease, and pancreatic cancer. But lack of information about the molecular structure of zinc transporters hampers the discovery of new drugs to bring zinc to proper levels (homeostasis) with other important elements. Researchers at Michigan State University (MSU) have taken a new step toward the development of…

Two studies from the Washington University School of Medicine in St. Louis, Missouri, reveal new insights into amyloid-β — the plaque-forming protein scientists believe is at the root of Alzheimer’s disease. Both studies homed in on the removal of amyloid-β from the brain, a process thought to be defective in Alzheimer’s…

Scientists at the Buck Institute for Research on Aging recently demonstrated that memory loss for patients with early Alzheimer’s disease can be reversed — a feat the research team managed through a 36-point approach called metabolic enhancement for neurodegeneration. The multidisciplinary program is the first to show that cognitive decline and…

Muses Labs has partnered with the George Washington Center for Integrative Medicine (GWCIM) to offer Alzheimer’s disease (AD) patients in the Washington, D.C. area the MEND Protocol (Metabolic Enhancement for Neuro-Degeneration), a comprehensive adherence program supporting patients and their caregivers that helps to improve patient outcomes. The MEND…

Alzheimer’s Therapeutic Research Institute (ATRI) at the University of Southern California, and Janssen Research & Development will collaborate for a  Phase 2/3 clinical trial of Jansen’s BACE blocker intended to delay or even prevent Alzheimer’s symptoms. The BACE blocker is a drug that prevents the action of an enzyme involved in…

The U.S. Senate Appropriations Committee  has forwarded a draft bill that could deliver nearly $1.4 billion in federal funds to Alzheimer’s disease (AD) research in 2017. In all health concerns related to the proposed bi-partisan bill, lawmakers recommend $34 billion – a $2 billion increase over fiscal year 2016 – to the…

Recent research published in The Lancet Neurology demonstrates that blood vessel changes such as arteriosclerosis and atherosclerosis in the brain are linked to Alzheimer’s disease. The findings suggest that investigating the mechanisms behind how blood vessel disease might contribute to the development of dementia might enable the…

Toronto researchers have examined the driving ability in people with cognitive impairments, including those with Alzheimer’s disease. The recent report, “A Systematic Review and Meta-Analysis of On-Road Simulator and Cognitive Driving Assessment in Alzheimer’s Disease and Mild Cognitive Impairment,” appeared in the Journal of…

Swedish researchers demonstrated that a heart medication can reduce the build-up of plaque in brain blood vessels in mice. If findings in this animal study hold true for humans, scientists may be closer to developing a drug against Alzheimer’s disease (AD). The study, “Platelets contribute to amyloid-β aggregation in cerebral…